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Thesis Abstract: Survival, virological and immunological outcomes of 
HIV-infected children accessing ART at South African primary health 
care clinics 
Background: South Africa faces the world’s largest pediatric HIV epidemic. 
Combination antiretroviral therapy (ART) is the only effective treatment for 
HIV virus suppression. Pediatric HIV care has traditionally been provided in 
academic research and tertiary care facilities, however efforts to improve ART 
availability for children are ongoing through decentralization. Tygerberg 
Hospital physicians with training in pediatric HIV management are providing 
care in seven community-based primary health care (PHC) clinics in the 
greater Cape Town region. ART initiation and ongoing ART management for 
those down-referred from tertiary and district level facilities are provided. The 
HIV-related outcomes of this cohort have yet to be reported. 
Methods: Research ethics approval from the South African Provincial 
Government of the Western Cape Department of Health, University of Cape 
Town and Stellenbosch University were acquired.  PHC HIV clinic rosters 
identified 848 patients under the age of 14, 613 of whom received at least one 
visit for ART management between 2004 and 2009.  A retrospective chart 
review was performed to collect baseline characteristics, site and date of ART 
initiation, serial CD4 and viral load levels, TB co-infection status, ART regimen 
changes, and clinical status at study closure.  Data was compiled in Excel 
spreadsheets and analyzed with STATA Statistical Software.  
Results: Nearly 80% of the PHC cohort initiated ART when diagnosed with 
WHO clinical stage III or IV disease; 60% had laboratory findings of either 
advanced or severe immunosuppression.  Those down-referred from tertiary 
and secondary care sites had significantly lower baseline CD4% (p=0.016), 
higher viral loads (p<0.001), and greater likelihood of TB co-infection 
(p=0.013) at the time of ART initiation.  Virological suppression was 
accomplished in 85% at the last study visit. Peak CD4 count reconstitution 
was seen after 36 months on ART. Documented mortality was 2.2%; maximal 
mortality (inclusive of those lost to follow-up) was 6.2%.  Highest maximal 
mortality risk was in the first three months of ART initiation.  All early deaths 
were in infants less than 6 months of age, or young children (11-15 months) 
with severe immunological suppression (CD4%-8.2%). Nearly half of these 
children were receiving treatment for TB co-infection.  Eighty percent of down-
referred children had virological suppression at the time of transfer; 96% 
maintained suppression. Nearly 80% of unsuppressed patients achieved 
suppression within 6 months of transfer; 75% of these children had previously 
been diagnosed with clinically significant virologic failure.   
Conclusions: Annually increasing numbers of less severely-ill ART initiates 
within the PHC network suggests successful ART roll-out in the Cape Town 
region.  Long-term ART management by physicians in PHC clinics yields high 
rates of viral load suppression and immune reconstitution, and low mortality. 
Highest mortality risk is in the first 3 months of ART among those <15 months 
of age. Down-referral for adherence-related virologic failure may allow 
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Many HIV-infected children in South Africa initiate antiretroviral therapy (ART) in a 
hospital based setting. However, with increasing demand for chronic HIV services and 
expanding expertise in paediatric HIV management, a large proportion of children now 
initiate or continue ART at community-based and primary health care facilities.  There 
are few descriptions in the literature of paediatric cohorts receiving community-based 
HIV care. This audit will describe the survival rate, virological and clinical outcomes of 
children who received paediatric HIV care at seven community-based ART facilities 
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South Africa’s Western Cape Province between January 2004 and January 2009. 
Baseline WHO HIV staging, immunological and virological characteristics will be 
described. Antiretroviral treatment regimen type and duration, as well as 
immunological and virological outcomes will be analysed 6 monthly from ART 
initiation.  Median survival and time to virological suppression will also be calculated.  
Confounding variables such as TB co-infection, ongoing WHO staging, and site of 
initiation and ongoing care will be taken into consideration. 
 
BACKGROUND AND SIGNIFICANCE 
 
WHO estimates that of the 2 million children living with HIV, 90% reside in sub-
Saharan Africai.  South Africa faces the world’s largest HIV epidemic with a 
staggering 280,000 children affectedii.  Perinatally acquired HIV infection in 
developing countries results in high mortality rates; without intervention 
approximately half of all HIV-infected children will die by their second birthdayiii,iv,v.   
Combination antiretroviral therapy (ART) is the only effective treatment 
available for the suppression of the HIV virus, and it is credited with the 
prevention of AIDS-related morbidity and mortalityvi,vii.  Children in developed 
countries receive ART as the standard of care, however it is estimated that less 
than ten percent of those living in resource-limited settings receive this life-
sustaining treatmentviii.  Barriers to treatment abound in sub-Saharan Africa: 
delayed diagnosis, limited number of paediatric clinicians, and lack of paediatric 
ART drug formulations in the public sector are among the most common cited.  
Management and provision of paediatric ART services requires sophisticated 
laboratory resources, clinical expertise, and reliable pharmaceutical distribution 
capacity.  Due to the high level of health care human resources and logistical 
coordination needed, paediatric ART distribution is commonly located at 
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population like South Africa, access to urban-based ART treatment facilities is 
associated with significant direct and indirect costs and contributes to the high 
rates of untreated children. 
In recent years, South Africa has expanded public sector HIV services and 
ART roll-out activities by addressing barriers to access.  Through the National 
Health Laboratory Service (NHLS), most clinicians now have access to rapid and 
accurate HIV diagnosis techniques (HIV Elisa and PCR), as well as CD4+ T-
lymphocyte and HIV viral load quantification monitoring tests.  Due to international 
funding sources such as PEPFAR and the Global Fund, training in paediatric ART 
management and stock of paediatric drug formulations has been increasingly 
available.   
In the Western Cape Province of South Africa, paediatric ART first became 
available to public sector patients in 2004.  Although children with complicated 
medical and social backgrounds maintain clinical follow-up at tertiary facilities, a 
decentralized approach for chronic HIV care has been adopted to increase 
community penetrance and availability of services for rural populations.  The 
Infectious Disease Clinic (IDC) at Tygerberg Children’s Hospital (TBH) supports a 
down-referral system by sending skilled paediatric clinicians to seven community-
based clinics located in the suburbs and rural areas surrounding Cape Town: 
Ikwezi, Grabouw, Kraaifontein, and Delft clinics; Eerste River, Helderberg and 
Karl Bremer Hospitals. 
ART efficacy is traditionally evaluated in three ways: repopulation of CD4+ 
T-lymphocyces, suppression of HIV viral load, and clinical recovery.  Many 
research studies have documented paediatric ART efficacy in the form of 
immunological, virological and clinical outcomes among those enrolled in 
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within developing countriesix,x,xi,xii,xiii,xiv,xv,xvi,xvii ,xviii ,xix,xx,xxi,xxii. Only two published 
accounts of community-based ART efficacy in a developing country have been 
identified to datexxiii ,xxiv.  
Implementation of a community-based ART program proved successful in 
the Zambian cohort as demonstrated by a doubling of CD4+ T-lymphocyte cell 
counts during the first year of ART. Unlike our Cape Town-based study 
population, the Zambian cohort was cared for by non-physician clinicians (nurses 
and physician assistants), and viral load testing was unavailable.  The treatment 
and monitoring strategy used for this population is therefore significantly different 
from the South African paediatric ART approach. 
The second assessment of paediatric ART outcomes in a developing 
country was performed in the Western Cape Province of South Africa. Bock et al. 
utilized the PGWC ART monitoring system to compare immunological and 
virological outcomes among HIV-infected children during the first 18 months of 
ART treatment at differential levels of health system facilities (tertiary, secondary 
and community hospitals, and PHC clinics).  Aggregate data was used to 
document deaths, loss to follow-up, trends in CD4 and HIV viral load levels, and 
initiation of second-line therapy for all children initiating ART in the Province. 
Although this study provided an excellent assessment of short-term 
outcomes, this proposal aims to provide a temporally extended assessment 
(potentially up to 5 years of follow-up) and address some of the limitations 
identified by the authors of the aforementioned study.  Bock et al. were able to 
glean a great amount of meaningful data from the monitoring system, yet their 
data was limited to elements captured by this electronic register.  Baseline 
characteristics (age, CD4, VL, WHO stage) as well as longitudinal information 










Detailed Protocol  Morsheimer, Myer, Cotton, Rabie, Dramowski 
 6 
therefore not available.  These characteristics, however, are well known to 
influence the survival, immunological and virological outcomes of HIV-infected 
children. 
 The monitoring system data analyzed in Bock et al.’s publication was 
appropriate for an assessment of a province-wide program and ART roll-out 
strategy as the aggregated data at the clinic and hospital level provided facility-
averaged outcomes. This study of paediatric ART outcomes among the TBH-IDC 
outreach cohort will allow for an outcome analysis that takes into account baseline 
and clinical data, and provides information on the individual patient level.  An 
analysis of this type will yield novel data that will add to the breadth and depth of 
the paediatric HIV literature. With the expansion of chronic ART services for 
paediatric patients, it is essential to document ART response in developing 
countries’ community-based clinics.  Documentation of the success of these 
programs at the provincial (Bock et al.) and individual level (this proposal) will 
provide valuable information to the PGWC management. 
 
HYPOTHESES  
HIV-infected children in PHC clinics receiving care from paediatric clinicians attain 
high levels of survival, immunological and virological outcomes.  
 
AIM 
To describe the survival, immunological and virological outcomes of children receiving 
ART at seven community-based facilities in the Western Cape Province of South 















1. To describe the number of children registered at each of the seven paediatric HIV 
clinics supported by the TBH-IDC community-based outreach service between 
January 2004 and January 2009.  
2. To describe baseline WHO HIV staging, immunological and virological 
characteristics of these children. 
3. To describe the ART regimen type and duration of treatment in this cohort of 
children. 
4. To describe the immunological and virological outcomes at 6 monthly intervals 
post-ART initiation, with stratification by baseline characteristics and place of 
treatment initiation (hospital versus clinic). 





This retrospective audit will document the number of children accessing ART 
at the seven paediatric ART clinics supported by the TBH-IDC outreach 
service: Ikwezi, Grabouw, Kraaifontein, and Delft clinics; Eerste River, 
Helderberg and Karl Bremer Hospitals.  The electronic patient register for 
each clinic will be acquired from the clinic database manager, and this 
document will be used to identify all children (< 14 years of age) newly started 
on ART or down-referred from TBH for continued treatment between January 
2004 and January 2009.  For each child identified from the register, data will 
be extracted from the IDC database (an electronic register of clinical and 
outcome data for children at the seven TBH-IDC supported ART clinics) for 
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ART initiation site, baseline WHO HIV stage, 6 monthly CD4 count and viral 
loads, and TB diagnoses.  Loss to follow-up and deaths will also be recorded.  
Data unavailable through electronic databases will be acquired through 




A retrospective, descriptive cohort study of HIV-infected children accessing care 
at seven community-based ART clinics in the Western Cape Province: Ikwezi, 





All HIV-infected children (less than 14 years of age) receiving ART at any one of 
the seven aforementioned paediatric community-based ART clinics supported by 
the TBH-IDC outreach service between January 2004 and January 2009.  Recent 
estimates suggest that the study population will include approximately 700 
children. 
 
STUDY SITES AND IMPACT ON RESOURCES 
 
TBH is a referral centre for complicated cases of paediatric HIV infection, with 
both inpatient and outpatient services offered. An outreach service supports 
seven HIV clinics, providing the expertise to initiate ART and accept down-
referrals from TBH for follow-up care. 
The TBH outreach clinicians who visit these sites weekly will introduce the 
study and provide the PGWC approval letter to the Clinic Director and/or Hospital 
Superintendent.  Once the institutional head agrees to participate, investigators 
will identify missing data points and provide a list of patients requiring manual 
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in obtaining files and capturing data after completion of their clinical duties. We 
anticipate that we will require minimal time on-site to obtain missing data directly 
from the clinic files.   
If additional research staff are utilized to supplement to the IDC doctors’ 
efforts (i.e. Drs. Morsheimer and Dramowski), one or two days of data collection 
will be planned for each site.  The outreach doctor will liaise with the head matron 
to identify a workspace for investigators that does not interfere with the flow of 
patient care or impose upon existing personnel.  Laptop computers are available 
so that investigators will not compete with staff for computing resources. It is not 
expected for existing staff to identify patient files on our behalf, as we do not want 
to increase their workload.  However, assistance from hospital clerks to locate and 
pull patient files may be requested if the site prefers not to allow clinical or 




Any HIV-infected child (less than 14 years of age) receiving ART and attending 
the paediatric HIV clinic at any one of the seven facilities supported by the TBH-
IDC outreach service between January 2004 and January 2009.  Any child 




Any HIV-infected child (less than 14 years of age) at a community-based HIV 
clinic NOT receiving ART between January 2004 and January 2009.  Any child 
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ART clinics supported by their clinicians.  This database is part of an umbrella 
data collection and interpretation project on pediatric HIV (ART-LINC 
Collaboration).  Ethical approval has previously been granted for collection and 
use of the ART-LINC data set.  This analysis will seek to specifically describe and 
assess the pediatric outcomes of those attending the seven clinics.   
Unlinked data will be extracted from the clinic database.  Where there are 
discrepancies in the data or possible queries, the patient will be identified and the 
paper records traced to verify information. A coded and de-identified data 
collection form will be used manually to extract data from the source document 
when necessaryi. The investigators will personally complete each data collection 
form thus helping to maintain data quality.  No patient identifiers will be used on 
the forms so as to protect the confidentiality of all cases. 
The primary risk to patients is a breach of confidentiality.  To minimize this, 
several steps will be undertaken: 
 An arbitrary anonymization key has been developed to remove any 
identifying information of the patients prior to data transfer 
 This key is held under strict secure conditions by the local collaborating 
clinician 
 Data entered in electronic databases will be password protected  
 Hard copies of the data will be stored in a locked, steel filing cabinet in a 
locked office. 
It is anticipated that the aforementioned system will work efficienty.   The use of 
depersonalized data from the ART-LINC Collaboration database has not yielded a 
breach of confidentiality to date. 
                                                















Data will be exported from the database and cleaned in Microsoft Excel.  Data 
quality will be checked by performing frequencies on categorical variables such as 
clinic name and by checking the range of continuous variables such as age and 
weight.  Data will be exported to STATA version 10 for more in-depth data 
analysis.   
Continuous variables will be compared using the Wilcoxon rank-sum test, 
and categorical variables will be compared using the Pearson Chi 2 test statistic.  
Kaplan-Meier curves will be fit to assess survival functions stratified by baseline 
CD4+ T-lymphocyte count (absolute count and percentage of total lymphocytes), 
WHO stage, age at ART-initiation, and site of ART initiation (TBH-IDC or PHC 
clinic). The log-rank test will be used to assess statistical difference among 
groups.  
Hazard ratios (HRs) for mortality will be estimated using Cox proportional 
hazards regression. For children receiving ART, we will calculate overall mortality 
rates, at 90 days of therapy, and after 90 days of therapy with exact 95% 
confidence limits.  
Multiple logistic regression modeling will be used to explore the association 
of certain characteristics (eg. baseline viral load, clinic site, site of ART initiation, 
TB co-infection) with attainment of virological suppression. Change in CD4 
percentage from ART initiation and HIV-1 RNA suppression below 400 copies/ml 
at 12 months will be modeled using linear and logistic regression, respectively, 
adjusting for values before ART, age at ART initiation and mode of presentation.  
Antiretroviral treatment regimen type and duration, as well as 
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Protocol development:  February 2009 
Ethical clearance:  March 2009 
Data collection:  May 2009 
Data analysis/Write up: June 2009 – February 2012 
Mentor review:  February 2012 - February 2013 




700 data collection forms @ 50c per page x 2 pages =  R700 
General printing costs =       R250 
Travel costs to each of the seven study sites =    R1000 
Database extraction and data cleaning =   R5000 
Total costs =        R6950 
These costs were covered by a pre-existing administrative grant from the Fogarty 
International Center, National Institutes of Health, USA. 
 
ETHICAL CONSIDERATIONS 
This protocol has been approved by the Human Research Ethics Committees at 
Stellenbosch University and the University of Cape Town. A waiver of patient 
consent has been granted by SU and UCT as a part of the ethics application.  
Permission has also been granted by the PGWC Department of Health. 
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and physical medical records. Electronic data will be kept on password protected 
computers, and forms containing identifying data will be stored in a locked, steel 
filing cabinet within a locked office at the University of Stellenbosch Faculty of 
Health Sciences Teaching Block.  
All research will be conducted in agreement with Good Clinical Practice 
guidelines (Dr. Morsheimer received GCP Certification in November 2008 with 
recertification in April 2013) and the Declaration of Helsinki version 2000xxv. 
 
APPLICATION OF STUDY FINDINGS 
Depersonalized data and aggregated analyses will be published in a peer-reviewed 
journal.  A report of results will also be provided to the PGWC. 
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A: Objectives of the literature review 
• Acquire a series of papers and documents that are credible, relevant,
and up-to-date with regards to pediatric HIV/AIDS treatment outcomes. 
• Identify outcome-related papers that include populations of HIV-infected
children on ART in developing countries. 
• Discover whether published evidence of long-term pediatric HIV
treatment outcomes among PHC or down-referred patients has been 
published to date. 
• Attain manuscripts and documents from large-scale organizations
(WHO, UNAIDS) for background epidemiology.
B & C: Literature search strategy, Quality review for inclusion
A systematic literature review was performed using the PICO strategy
(P: population, I/E: intervention/exposure, C: comparison group, O: outcomes)
to identify literature regarding pediatric ART treatment outcomes (Richardson 
et al., 1995). PubMed MeSH terms were used, and search filters were
applied to maximize effective identification of literature while limiting the study
type (“Humans, Clinical Trial, Meta-analysis, Randomized Clinical Trial,
Review”) and subject age (“All Infant: birth-23 months, All Child: 0-18 years”).
Initial searches yielded large numbers of applicable studies (4,503 to 189,247
hits), therefore boolean terms were used to layer search outcomes so as to
create an aggregate search that was most specific to my research topic.
(Please see “Part D: Appendices” for complete details of systematic literature
review, including MeSH search terms and outcomes for the primary search
performed). Despite using a “venn diagram”-type approach to narrow search











terms failed to yield sentinel and desired publications; therefore manual
review was performed on this large number of citations. A methodical review
of all abstracts was performed with care to identify relevant literature (Please
see “Part D: Appendicies” for topics excluded to improve quality/relevance of
search engine output) and classify literature into the following categories:
epidemiology, barriers to care, long-term outcomes (further delineated as
developed countries/international multisite organized trials, resource-limited
academic settings, resource-limited community-based settings, PHC’s,
comparison of settings), and public health perspectives.
An additional focused search aimed at papers addressing outcomes
among individuals receiving care in a decentralized or down-referral program
was performed. The UNAIDS publications website
(http://www.unaids.org/en/resources/publications/unaidspublications/2012/) 
was utilized to download policy and epidemiology resources. Research
collaborators provided a few resources, and reading the references of highly
relevant papers identified further desired citations.
Full publications were downloaded as pdf files through academic
access provided by the University of California, San Francisco library.
References were ultimately uploaded into RefWorks Web Based Bibliographic
Management Software.
D: Summary of the Literature 
Although 2009 global prevalence estimates of children living with HIV 
has risen to 2.5 million [1.7 million–3.4 million], mortality among those under 











Programme on HIV/AIDS (UNAIDS), 2010). Rising prevalence and 
decreasing mortality is likely secondary to efforts to improve pediatric access 
to life-saving ART. Overall, incidence rates are decreasing, with vertical 
transmission resulting in 370,000 children born with HIV in 2009 (decreased 
from 500,000 cases in 2001) and 1200 new infections every day (WHO, 2010). 
Sub-Saharan Africa continues to shoulder the largest share of the HIV 
disease burden with 68% of the overall global patient load and 90% of the 
pediatric cases (Joint United Nations Programme on HIV/AIDS (UNAIDS), 
2010). 2.3 million [1.4-3.1 million] children are estimated to live with HIV in 
sub-Saharan Africa. Sub-Saharan Africa reached 54% PMTCT coverage in 
2009, which indicates interval improvement (15% in 2005) with room for 
further roll-out. HIV treatment expansion activities are reaching larger 
numbers of adults and children in need of pharmacologic intervention with 
every passing year; an estimated 37% of all eligible patients in Southern 
Africa in 2009 received ART, compared to 2% in 2002 (U. a. U. WHO, 2010). 
ART access among children in need is estimated at 26% (Joint United 
Nations Programme on HIV/AIDS (UNAIDS), 2010). 
South Africa continues to have the largest national HIV epidemic, with 
an estimated 5.6 million [5.4 million–5.8 million] individuals living with HIV, 
including 330,000 [190,000 – 440,000] children. Despite achieving a nearly 
90% PMTCT coverage rate by 2009 (Joint United Nations Programme on 
HIV/AIDS (UNAIDS), 2010), children continue to be born with and die from 
HIV at alarming rates. Perinatally acquired HIV infection results in high 
mortality rates; without intervention approximately one third of HIV-infected 











children will not celebrate their second (Dabis et al., 2001; Dunn & HIV 
Paediatric Prognostic Markers Collaborative Study Group, 2003; Spira et al., 
1999).  Thirty five percent of South African children who die before their fifth 
birthday fall victim to an AIDS-related demise (Shisana, 2010). 
Combination antiretroviral therapy (ART) is the only effective treatment 
available for the suppression of the HIV virus, and this pharmacologic 
intervention is credited with the prevention of AIDS-related morbidity and 
mortality (de Martino et al., 2000; Gibb et al., 2003). The majority of children in 
developed countries receive ART as the standard of care upon initial 
diagnosis, however it is estimated that only one in four children living in sub-
Saharan Africa receives this life-sustaining treatment (Joint United Nations 
Programme on HIV/AIDS (UNAIDS), 2010). Des ite substantial evidence that 
early intervention with ART is life and morbidity sparing (Berk et al., 2005; 
Johnson et al., 2011; Violari et al., 2008), the age of those accessing ART 
services remains high in developing countries (M. Davies et al., 2011; KIDS-
ART-LINC Collaboration, 2008). 
Although generally the political will is present for countries to roll-out 
HIV therapy, barriers to ART programs in developing countries abound: 
inadequate infrastructure, archaic laboratories, paucity of adequately-trained 
health care human resources, patented medications and vulnerable pharmacy 
supply chain, disconnected care provision models (i.e. separate tuberculosis, 
ART, PHC and pediatric clinics), and a marked disparity between rural and 
urban access to care sites (Ojikutu, 2007; Ojikutu, Jack, & Ramjee, 2007). 
ART roll-out activities in South Africa have come under particular criticism due 











(Ojikutu et al., 2007). Although some endorse volitional prolongation to ART
scale-up (Nattrass, 2006), unique political, cultural and infrastructural deficits
must be considered as contributing factors. Addressing the magnitude of the
need for services within a public health system with limited means to mend
long-standing inequities in health care provision has proven a formidable task.
South Africa, now home to 5.6 million individuals living with HIV (Joint United
Nations Programme on HIV/AIDS (UNAIDS), 2010), has taken up
partnerships with numerous multinational charitable organizations and NGOs
to hasten roll-out services. As a reflection of improved ART access,
preliminary death registry analysis performed by the Medical Research
Council of South Africa suggests decreasing annual mortality rates 
attributable to HIV (Pillay-van Wyk et al., 2013) 
Although larger proportions of South Africans are accessing life-saving
ART, services for pediatric patients lag behind. Delayed diagnosis due to lack
of capacity for HIV DNA PCR testing, limited number of clinicians and staff
trained to provide pediatric HIV management, scarcity of pediatric ART drug
formulations, and limited access to birth certificates for rural-born children
(required for enrollment) are among the most common pediatric-specific 
barriers cited (Balcha & Jeppsson, 2010; Fredlund & Nash, 2007; Meyers et
al., 2007). Successful provision of pediatric ART services ultimately requires
sophisticated laboratory resources, clinical expertise, and reliable
pharmaceutical distribution capacity – resources often lacking at primary and
secondary care facilities. Due to the high level of health care human
resources and logistical coordination needed, pediatric ART distribution has











centers and more recently, district-level hospitals. As of 2007, the majority of 
children in Gauteng Province continued to receive ART care in tertiary 
facilities due to lack of pediatric clinicians with HIV care expertise (Meyers et 
al., 2007). For a predominantly rural-based population like South Africa, 
access to urban tertiary ART treatment facilities is associated with significant 
direct and indirect costs, which undoubtedly contribute to the high rates of 
untreated children. 
In the Western Cape Province of South Africa, pediatric ART first became 
available to public sector patients in 2004. Barriers to diagnosis and 
monitoring were addressed with expansion of National Health Laboratory 
Service (NHLS) capacity; access to rapid and accurate HIV diagnosis 
techniques (HIV Elisa and PCR), as well as CD4+ T-lymphocyte and HIV viral 
load quantification monitoring became routinely available (given the care site 
to laboratory transportation chain was intact). International funding sources 
such as PEPFAR and the Global Fund not only ensured a reliable supply-
chain of pediatric drug formulations, but also expanded access to heath-
worker training in pediatric ART management. Although the WHO has been 
recommending a decentralized, public health-centered approach for ART 
delivery in resource-limited settings since 2000 (Gilks et al., 2006; Qazi & 
Muhe, 2006), it was only in conjunction with the aforementioned 
advancements many years later that an integrated, primary health care (PHC) 
model for pediatric ART delivery became feasible. 
As evidence of the Western Cape Province’s commitment to WHO 
recommendations for community-based ART delivery, the proportion of 











Children’s Hospital, Groote Schuur Hospital at the University of Cape Town, 
and Tygerberg Children’s Hospital at Stellenbosch University) dropped from 
78.4% in 2004 to 38% in 2006 (Meyers et al., 2007) . Training in routine 
pediatric care, as well as the complexities of ART management, was identified 
as a rate-limiting step for rapid expansion of pediatric community-based care 
in Cape Town by international funders. In order to overcome this barrier and 
expedite access to high quality pediatric ART care for those in the suburbs 
and rural areas surrounding Cape Town, pediatric clinicians from the 
Infectious Disease Clinic at Tygerberg Children’s Hospital (TBH) were funded 
by PEPFAR to travel weekly to seven PHC clinics: Ikwezi, Grabouw, 
Kraaifontein, and Delft clinics; Eerste River, Helderberg and Karl Bremer 
Hospitals. 
Three distinct groups of HIV-infected children receive care from TBH 
pediatric clinicians within the PHC network: individuals not on ART 
undergoing periodic evaluation for clinical or immunological qualification for 
ART; those initiating and continuing ART within the PHC network; and 
children down-referred on ART from tertiary, secondary and research-
affiliated facilities. Long-term outcomes among ART naïve pediatric patients 
who initiate care in PHC clinics, as well as those who are down-referred 
between tiered levels of the healthcare delivery system (Please see Part D: 
Appendices, Supplementary Tables and Figures, Figure 1, for a reproduction 
of the “Health Services Pyramid”, demonstrating the hierarchical levels of 
healthcare provision within Provincial Health Systems) (Gold et al., 1994; 
Turnock, 2009) are of particular interest to public health stakeholders as this 












ART efficacy is traditionally evaluated in three ways: repopulation of 
CD4+ T-lymphocytes, suppression of HIV viral load, and survival. Numerous 
research studies have documented pediatric ART efficacy in the form of 
immunological, virological and clinical outcomes among those enrolled in 
programs based in developed countries (DC), however these outcomes are 
thought to be significantly different from those documented in resource-limited 
settings (RLC). A recent large-scale meta-analysis of published pediatric 
outcomes (including both papers and conference abstracts) was performed to 
compare pediatric ART outcomes stratified by United Nations designation as 
resource-limited (Peacock- Villada, Richardson, & John-Stewart, 2011). 
Baseline higher viral load and lower CD4 levels were identified in RLC cohorts. 
After 12 months of ART, mean CD4% was found to be 24% among RLC and 
27% in DC children (p=0.03); VL suppression (<400 copies per ml) was 65% 
among RLC and 49% of DC patients (p=0.4); and mortality rates were 5-9 
times higher (p=0.002) in RLC studies (“7.6% vs 1.6% and 8 vs 0.9 for 
motality percentage and DPCY”, p<0.001). 
Efforts preceding Peacock’s study (Peacock-Villada et al., 2011) took 
either a more focused approach to pooled data from RLC publications 
(Ciaranello et al., 2009) or findings originating from sub-Saharan Africa 
(Sutcliffe, van Dijk, Bolton, Persaud, & Moss, 2008). As many of the papers 
utilized data included in Peacock’s study it is not surprising that results were 
similar. Ciaranello et.al. estimate one year CD4% improvement of 13.7%, 
virologic suppression among 70%, and mortality rates ranging from 0 to 











severe clinical disease upon initiation of ART. The median rise in CD4% T 
lymphocytes while on ART was reported at 6-monthly intervals: “7-13.8% at 6-
8 months, 10-16% at 12-15 months, 10% at 24 months and 21% at 36 
months”. Serial viral loads were also included in longitudinal analysis: “viral 
suppression [<400 copies/ml] was…46-81% at 6 months…49-81% at 12 
months…50% of children at 24 months, 47-83% at 36 months, and 45% at 42 
months”. 
Inclusive of cohorts of patients representing the majority of South 
Africa’s Provinces, a prospective database created by the NIH-funded 
“International epidemiologic Databases to Evaluate AIDS (IeDEA) Southern 
Africa collaboration” (IeDEA-SA) aims to provide insight into treatment 
outcomes within the South African national ART rogramme (Cornell et al., 
2009). According to results reportedly representative of 20% of children 
enrolled in the South African national treatment program, most children were 
severely ill at the onset of ART treatment. Viral load suppression (<400 
copies/ml) rates were consistently over 80% throughout the 36 month 
monitoring period and a mortality rate at 3 years of 7.7% was observed (M. A. 
Davies et al., 2009). Additionally the 3-year probability of developing virologic 
failure (as defined by “2 consecutive unsuppressed viral loads with the second 
being >1000 copies/ml, after more than 24 weeks of therapy”, and to be 
hereby denoted as VF) was 19.3% with independent association between VF 
and PI-containing regimens (M. Davies et al., 2011). 
The vast majority of the aforementioned analyses, despite inclusion of 
RLC’s and African children, included data pooled from research studies where 











unique approach to gain insight into more generalizable outcomes, Bock et.al. 
published the first African study utilizing aggregate public health data (routine 
data collected between 2004 and 2006 by the provincial ART monitoring 
system) to compare pediatric ART outcomes within the tiered healthcare 
delivery model (Bock, Boulle, White, Osler, & Eley, 2008). Stratification by 
academic or tertiary hospitals, regional referral hospitals, as well as district-
level hospitals and PHC clinics revealed comparable outcomes. Proportions 
of children with CD4% greater than 20% rose from 60.6% at 6 months to 
96.8% at 18 months, while VL suppression rates were similar to those noted 
in other studies (72.3% at 6 months, 76.8% at 18 months). Low rates of 
regimen change were observed overall without any PHC-enrolled children 
changing to second line ART. 
Although aggregate surveillance data yields representative and highly 
powered outcomes, this study design is limited in its analysis of those who 
change levels of care during the duration of their ART therapy (i.e. down 
referral from tertiary care center to PHC clinic). As South African roll-out 
activities allow for larger numbers of young, less severely-ill patients to enroll 
for services in a decentralized system over time (Fatti, Bock, Eley, Mothibi, & 
Grimwood, 2011), a growing proportion of patients will also become eligible 
for down-referral from specialized sites for continuation of care in PHC clinics. 
Two large, recently published studies were identified and directly address the 
long-term outcomes of those down-referred from tertiary to PHC clinics for 
ongoing ART management. 
A retrospective cohort analysis of Malawian adults and children 











differential outcomes depending on whether patients continued care at a 
tertiary hospital clinic or were down-referred to PHC clinics (Chan et al., 2010). 
In order to qualify for decentralized care, patients were required to be stable 
on first-line ART for at least three months without drug toxicity, active 
opportunistic infections, or adherence issues. Those down-referred ultimately 
had lower mortality and default rates. Although community-based clinical 
expertise was provided every 1-2 months by Baylor Pediatric AIDS Corps 
Consultants, larger proportions of children continued to receive ongoing care 
in the tertiary facility. 
A recent prospective, case-controlled South African study of the down-
referral of stable adult patients from a large, university-associated clinic to 
nurse-run PHC clinics yielded encouraging results: those down-referred had 
comparable, in cases better, outcomes than those continuing care at the 
treatment-initiation clinic (Brennan et al., 2011). Those down-referred had 
lower motality and loss to follow-up rates. Although these adult down-referred 
patients were heavily screened (more than 11 months on ART, at least two 
sequential VL levels <400 copies/ml, no opportunistic infections, and full 
immune reconstitution with CD4>200 cells/ul), the findings of this large-scale, 
rigorously-designed study of down-referral outcomes are encouraging. 
As evidence mounts for successful initiation of pediatric ART care in 
rural and urban community-based PHC clinics (Barth et al., 2011; Bekker, 
Myer, Orrell, Lawn, & Wood, 2006; Bock et al., 2008; Bolton-Moore et al., 
2007; van Griensven et al., 2008), the need for study of pediatric down-
referral outcomes remains. Although children with complicated medical and 











decentralized approach for chronic HIV care has been successfully adopted in 
RLC’s, including South Africa, to increase community penetrance and 
availability of services for urban and rural populations alike. 
 
E: Identification of gaps in the literature 
 
Although data from some of the patients included in the “Survival, virological 
and immunological outcomes of HIV-infected children accessing ART at 
South African Community-based clinics” study have already been published in 
the pediatric ART Western Cape Province analysis by Bock et.al., this study 
provides additional insight into outcomes among Cape Town children. Our 
data set includes a further 3 years of follow-up data, reflecting 
the ability to report 5-year outcomes, as well as the unique capacity to 
analyze children who cross health-system strata through a down-referral 
process for ongoing ART management. Unlike nurse-run PHC studies, 
pediatric clinicians provide direct care to PHC network patients, thus allowing 
capacity to manage unstable down-referred patients as well as those requiring 
second line therapy. Additionally, a gap of literature exists describing the 
side-by-side longitudinal care of evolving dual-cohorts – those who initiate 




Balcha, T. T., & Jeppsson, A. (2010). Outcomes of antiretroviral treatment: A 
comparison between hospitals and health centers in Ethiopia. Journal of 
the International Association of Physicians in AIDS Care (Chicago, Ill.: 
2002), 9(5), 318-324. 











& Geelen, S. P. (2011). Long-term outcome of children receiving 
antiretroviral treatment in rural South Africa: Substantial virologic failure on 
first-line treatment. The Pediatric Infectious Disease Journal, 30(1), 52-56.  
Bekker, L. G., Myer, L., Orrell, C., Lawn, S., & Wood, R. (2006). Rapid scale-
up of a community-based HIV treatment service: Programme performance 
over 3 consecutive years in Guguletu, South Africa. South African Medical 
Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde, 96(4), 315-320. 
Berk, D. R., Falkovitz-Halpern, M. S., Hill, D. W., Albin, C., Arrieta, A., Bork, J. 
M., et al. (2005). Temporal trends in early clinical manifestations of 
perinatal HIV infection in a population-based cohort. JAMA : The Journal 
of the American Medical Association, 293(18), 2221-2231. 
Bock, P., Boulle, A., White, C., Osler, M., & Eley, B. (2008). Provision of 
antiretroviral therapy to children within the public sector of South Africa. 
Transactions of the Royal Society of Tropical Medicine and Hygiene, 
102(9), 905-911. 
Bolton-Moore, C., Mubiana-Mbewe, M., Cantrell, R. A., Chintu, N., Stringer, E. 
M., Chi, B. H., et al. (2007). Clinical outcomes and CD4 cell response in 
children receiving antiretroviral therapy at primary health care facilities in 
Zambia. JAMA : The Journal of the American Medical Association, 298(16), 
1888-1899. 
Brennan, A. T., Long, L., Maskew, M., Sanne, I., Jaffray, I., MacPhail, P., et al. 
(2011). Outcomes of stable HIV-positive patients down-referred from a 
doctor-managed antiretroviral therapy clinic to a nurse-managed primary 












Chan, A. K., Mateyu, G., Jahn, A., Schouten, E., Arora, P., Mlotha, W., et al. 
(2010). Outcome assessment of decentralization of antiretroviral therapy 
provision in a rural district of malawi using an integrated primary care 
model. Tropical Medicine & International Health: TM & IH, 15 Suppl 1, 90-
97. 
Ciaranello, A. L., Chang, Y., Margulis, A. V., Bernstein, A., Bassett, I. V., 
Losina, E., et al. (2009). Effectiveness of pediatric antiretroviral therapy in 
resource-limited settings: A systematic review and meta-analysis. Clinical 
Infectious Diseases : An Official Publication of the Infectious Diseases 
Society of America, 49(12), 1915-1927. 
Cornell, M., Technau, K., Fairall, L., Wood, R., Moultrie, H., van Cutsem, G., 
et al. (2009). Monitoring the South African national antiretroviral treatment 
programme, 2003-2007: The IeDEA southern Africa collaboration. South 
African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde, 
99(9), 653-660. 
Dabis, F., Elenga, N., Meda, N., Leroy, V., Viho, I., Manigart, O., et al. (2001). 
18-month mortality and perinatal exposure to zidovudine in west Africa. 
AIDS (London, England), 15(6), 771-779. 
Davies, M., Moultrie, H., Eley, B., Rabie, H., Van Cutsem, G., Giddy, J., et al. 
(2011). Virologic failure and second-line antiretroviral therapy in children in 
South Africa -- the IeDEA southern Africa collaboration. Journal of 
Acquired Immune Deficiency Syndromes, 56(3), 270. 
Davies, M. A., Keiser, O., Technau, K., Eley, B., Rabie, H., van Cutsem, G., et 
al. (2009). Outcomes of the South African national antiretroviral treatment 











African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde, 
99(10), 730-737. 
de Martino, M., Tovo, P. A., Balducci, M., Galli, L., Gabiano, C., Rezza, G., et 
al. (2000). Reduction in mortality with availability of antiretroviral therapy 
for children with perinatal HIV-1 infection. Italian register for HIV infection 
in children and the Italian national AIDS registry. JAMA: The Journal of the 
American Medical Association, 284(2), 190-197. 
Dunn, D., & HIV Paediatric Prognostic Markers Collaborative Study Group. 
(2003). Short-term risk of disease progression in HIV-1-infected children 
receiving no antiretroviral therapy or zidovudine monotherapy: A meta-
analysis. Lancet, 362(9396), 1605-1611. 
Fatti, G., Bock, P., Eley, B., Mothibi, E., & Grimwood, A. (2011). Temporal 
trends in baseline characteristics and treatment outcomes of children 
starting antiretroviral treatment: An analysis in four provinces in South 
Africa, 2004 2009. Journal of Acquired Immune Deficiency Syndromes 
(1999), 58(3), e60-7. 
Fredlund, V. G., & Nash, J. (2007). How far should they walk? Increasing 
antiretroviral therapy access in a rural community in northern 
KwaZuluNatal,South Africa. The Journal of Infectious Diseases, 196 Suppl 
3, S469-73. 
Gibb, D. M., Duong, T., Tookey, P. A., Sharland, M., Tudor-Williams, G., 
Novelli, V., et al. (2003). Decline in mortality, AIDS, and hospital 
admissions in perinatally HIV-1 infected children in the United Kingdom 
and Ireland. BMJ (Clinical Research Ed.), 327(7422), 1019. 











al. (2006). The WHO public-health approach to antiretroviral treatment 
against HIV in resource-limited settings. Lancet, 368(9534), 505-510. 
Gold, M., Teutsch, S., McCoy, K., Shaffer, P., Siegel, J., Johnson, P., et al. 
(1994). For a healthy nation, returns on investment in public health. 





Johnson, L. F., Davies, M. A., Moultrie, H., Sherman, G. G., Bland, R. M., 
Rehle, T. M., et al. (2012). The effect of early initiation of antiretroviral 
treatment on pediatric AIDS mortality in South Africa: a model-based 
analysis. The Pediatric Infectious Disease Journal, 31(5), 474-80. 
Joint United Nations Programme on HIV/AIDS (UNAIDS). (2010). Global 
report: UNAIDS report on the global AIDS epidemic 2010. Switzerland: 
WHO Library Cataloguing-in-Publication Data. (UNAIDS Global Report 
2010) 
KIDS-ART-LINC Collaboration. (2008). Low risk of death, but substantial 
program attrition, in pediatric HIV treatment cohorts in sub-Saharan Africa. 
Journal of Acquired Immune Deficiency Syndromes (1999), 49(5), 523-531. 
Meyers, T., Moultrie, H., Naidoo, K., Cotton, M., Eley, B., & Sherman, G. 
(2007). Challenges to pediatric HIV care and treatment in South Africa. 
The Journal of Infectious Diseases, 196 Suppl 3, S474-81. 
Nattrass, N. (2006). South Africa's "rollout" of highly active antiretroviral 











Syndromes, 43(5), 618-623. 
Ojikutu, B. (2007). Introduction: The realities of antiretroviral therapy rollout: 
Overcoming challenges to successful programmatic implementation. The 
Journal of Infectious Diseases, 196 Suppl 3, S445-8. 
Ojikutu, B., Jack, C., & Ramjee, G. (2007). Provision of antiretroviral therapy 
in South Africa: Unique challenges and remaining obstacles. The Journal 
of Infectious Diseases, 196 Suppl 3, S523-7. 
Peacock-Villada, E., Richardson, B. A., & John-Stewart, G. C. (2011). Post- 
HAART outcomes in pediatric populations: Comparison of resource limited 
and developed countries. Pediatrics, 127(2), e423-41. 
Pillay-van Wyk, V., Msemburi, W., Laubscher, R., Dorrington, R.E., 
Groenewald, P., Matzopoulos, R., Prinsloo, M., Nojilana, B., Nannan, N., 
Gwebushe, N., Vos, T., Somdyala, N., Sithole, N., Neethling, I., Nicol, E., 
Joubert, J., Rossouw, A., Bradshaw, D. (2013). Second National Burden of 
Disease Study South Africa: national and subnational mortality trends, 
1997-2009. The Lancet, 381, S113. 
Qazi, S. A., & Muhe, L. M. (2006). Integrating HIV management for children 
into the integrated management of childhood illness guidelines. 
Transactions of the Royal Society of Tropical Medicine and Hygiene, 
100(1), 10-13. 
Richardson, W.S., Wilson, M.C., Nishikawa, J., Hayward, R.S. (1995). The 
well-built clinical question: a key to evidence-based decisions. ACP J Club, 
123(3), A12-13. 
Shisana, O. (2010). South African national HIV prevalence, incidence, 











Cape Town, South Africa: HSRC Press. 
Spira, R., Lepage, P., Msellati, P., Van De Perre, P., Leroy, V., Simonon, A., 
et al. (1999). Natural history of human immunodeficiency virus type 1 
infection in children: A five-year prospective study in Rwanda. mother-to-
child HIV-1 transmission study group. Pediatrics, 104(5), e56. 
Sutcliffe, C. G., van Dijk, J. H., Bolton, C., Persaud, D., & Moss, W. J. (2008). 
Effectiveness of antiretroviral therapy among HIV-infected children in sub-
Saharan Africa. The Lancet Infectious Diseases, 8(8), 477-489. 
Turnock, B. (2009). Public health: What it is and how it works (Fourth ed.). 
United States of America: Jones and Bartlett Publishers LLC.
van Griensven, J., De Naeyer, L., Uwera, J., Asiimwe, A., Gazille, C., & Reid,
T. (2008). Success with antiretroviral treatment for children in Kigali,
Rwanda: Experience with health center/nurse-based care. BMC Pediatrics, 
8, 39. 
Violari, A., Cotton, M. F., Gibb, D. M., Babiker, A. G., Steyn, J., Madhi, S. A.,
et al. (2008). Early antiretroviral therapy and mortality among HIV-infected 
infants. The New England Journal of Medicine, 359(21), 2233-2244. 
WHO. (2010). Antiretroviral therapy for HIV infection in infants and children:
Towards universal access. recommendations for a public health approach. 
2010 revision. Geneva, Switzerland: WHO Press. 
WHO, U. a. U. (2010). Towards universal access: Scaling up priority 
HIV/AIDS interventions in the health sector. Progress report 2010. 








































(a) Full Title: Successful pediatric HIV management within a South African 
decentralization model of ART Delivery  
 
(b) Authors and Affiliations 
 
Megan Marie Morsheimer, MD: University of Cape Town, Children’s Hospital 
of Philadelphia 
 
Angela Dramowski, MBCHB, MMed (Paeds ID): Tygerberg Children’s 
Hospital 
 
Mark Cotton, MD, PhD: Tygerberg Children’s Hospital 
 
Helena Rabie, MBCHB, MMed (Paeds ID): Tygerberg Children’s Hospital 
 
(c/d) Correspondence Address 
 
Dr. Megan Morsheimer 
Children’s Hospital of Philadelphia 
Division of Allergy and Immunology 
3550 Market Street, Third Floor 
Philadelphia, PA  19104  USA 
 
Phone: 215-590-2549 
Email: morsheimerm@email.chop.edu; megan.morsheimer@gmail.com  
 
(e) M.M.M and A.D. were supported by the National Institutes of Health Office 
of the Director, Fogarty International Centre, through the International Clinical 
Research Fellows Program at Vanderbilt University (R24 TW007988). 
 
(f) Key words: Pediatric, HIV, ART, decentralized, primary health care 
 
(g) Pediatric ART Outcomes within a Decentralization Model 
 














Successful pediatric HIV management within a South African 
decentralization model of ART delivery 
 
Background: South Africa faces the world’s largest pediatric HIV epidemic. 
Efforts to expand antiretroviral therapy (ART) access are ongoing through 
decentralization of care to primary health care (PHC) clinics. Tygerberg 
Hospital physicians provide ART initiation and long-term management for 
pediatric patients in seven PHC clinics in the Cape Town region. HIV-related 
outcomes of this cohort have yet to be reported. 
Methods: Clinic rosters identified 613 children <14 years of age who received 
ART management between 2004 and 2009. A retrospective chart review 
collected baseline characteristics, site and date of ART initiation, serial CD4 
and viral load levels, TB co-infection status, ART regimen changes, and 
clinical status at study closure. 
Results: Sustained virologic suppression and CD4 reconstitution was seen in 
over 80% of patients. Documented mortality was 2.2%.  All early deaths were 
among infants <15 months of age. Nearly 80% of those with unsuppressed VL 
at the time of down-referral achieved suppression within 6 months; 75% of 
these children had clinically significant virologic failure at transfer. 
Conclusions: Annually increasing numbers of less severely-ill ART initiates 
within the PHC network suggests successful ART roll-out in the Cape Town 
region. Long-term ART management by physicians in PHC clinics yields high 
rates of viral load suppression and immune reconstitution, and low mortality. 
Highest mortality risk is in the first 3 months of ART among those <15 months 
of age. Down-referral for adherence-related virologic failure may allow 













WHO estimates that of the 2.5 million children living with HIV, 90% reside in sub-
Saharan Africa 1.  South Africa faces the world’s largest HIV epidemic with a 
staggering 330,000 children affected 1.  Perinatally acquired HIV infection results 
in high mortality rates; without intervention approximately half of all HIV-infected 
children will die by their second birthday 2-4.  35% of South African children who 
die before their fifth birthday fall victim to an AIDS-related demise 5. 
Combination antiretroviral therapy (ART) is the only effective treatment 
available for the suppression of the HIV virus, and it is credited with the 
prevention of AIDS-related morbidity and mortality 6, 7.   Children in developed 
countries receive ART as the standard of care upon initial diagnosis, however it is 
estimated that only one in four children living in sub-Saharan Africa receives this 
life-sustaining treatment 1.  Barriers to pediatric treatment abound in sub-Saharan 
Africa: delayed diagnosis due to lack of capacity for HIV DNA PCR testing, 
inadequate number of clinicians and staff trained to provide pediatric HIV 
management, and scarcity of pediatric ART drug formulations are among the 
most commonly cited systemic obstacles 8-10.   
WHO has been recommending a decentralized, public health-centered 
approach for HIV care in resource-limited settings since 2000 11, 12.  Due to the 
high level of health care human resources and logistical coordination needed to 
maintain a pediatric clinical practice and pharmacy, pediatric ART distribution has 
historically been located at tertiary centers and established research units in 
urban settings.  For a predominantly rural and peri-urban based population like 
that in South Africa, access to urban tertiary care ART treatment facilities is 












In the Western Cape Province of South Africa, pediatric ART first became 
available to public sector patients in 2004.  With concurrent expansion of the 
National Health Laboratory Service (NHLS) capacity and international funding for 
infrastructure and healthcare workforce training, a decentralized approach to ART 
delivery was actualized.  International funders, however, identified mastering the 
complexities of ART management in addition to routine pediatric care as a 
surmountable rate-limiting step.  To expedite access to high quality care for HIV-
infected children in the suburbs and rural areas surrounding Cape Town, 
PEPFAR and the South African government funded pediatric clinicians from the 
Infectious Disease Clinic (IDC) at Tygerberg Children’s Hospital (TBH) to provide 
direct care within seven primary health care (PHC) outreach clinics: Ikwezi, 
Grabouw, Kraaifontein, and Delft clinics; Eerste River, Helderberg and Karl 
Bremer Hospitals.  Between 2004 and 2006 a decentralized approach to care 
resulted in a decrease in the proportion of Cape Town children receiving services 
at tertiary centers (Red Cross War Memorial Children’s Hospital, Groote Schuur 
Hospital at the University of Cape Town, and Tygerberg Children’s Hospital at 
Stellenbosch University) from 78.4% to 38% 10 .   
As evidence mounts for successful initiation of pediatric ART care in rural 
and urban community-based PHC clinics 13-17, the need to evaluate pediatric 
down-referral outcomes remains.  Two large studies performed in sub-Saharan 
Africa demonstrated lower mortality and default rates among down-referred 
patients; it is notable, however, that the option of down-referral was only offered 
to stable, compliant patients on first-line ART 18, 19.  Chan et al.’s Malawian cohort 












acknowledge that the majority of children remained in the tertiary clinic at the end 
of the study period. 
A unique cohort of children has developed within the PHC network as 
clinician-driven longitudinal care was provided for both ART-naïve initiates and 
those down-referred from tertiary facilities.  Characterization of this cohort 
provides insight into long-term immunologic and virologic outcomes of PHC-
managed children.  Analysis of the outcomes of children who cross health-system 
strata through a down-referral process to initiate community-based ART 
management may identify characteristics predictive of success. 
 
MATERIALS AND METHODS 
 
Patients seeking HIV management at PHC clinics received opportunistic 
infection screening, ART regimen oversight and dose adjustment for growth, 
adverse event monitoring with clinical examination and routine blood work, 
and referral for nutritional support as needed.  Services were performed in 
accordance with South African National protocols, which are based on WHO 
guidelines.   
Children under 14 years of age who were either newly started on ART 
or down-referred for continued ART management between January 2004 and 
January 2009 within one of seven PHC clinics supported by the TBH outreach 
physicians was identified by PHC HIV clinic register for inclusion.  
Retrospective cohort data was gleaned from the IDC database (an electronic 
register of clinical and outcome data for children at the seven outreach clinics) 
so as to create a novel database including date of birth, first visit date at an 
HIV clinic, ART initiation date, ART initiation site, baseline WHO clinical stage, 












and deaths were also extracted.  Data not available within the IDC database 
was either retrieved from the NHLS laboratory server or through clinic-based 
paper chart evaluationi.  Patients identified without follow-up data (due to ART 
initiation, transfer-in or transfer-out, death, or loss to follow-up within 6 months 
of identification within the PHC network) were categorized as “baseline”; those 
with at least 6 months of follow-up data within the PHC network were 
assigned to the “longitudinal” cohort.  
Serial CD4 counts and HIV viral loads were ordered by physicians at 6 
month intervals as part of standard HIV-care protocols in the Western Cape 
Province.  Lab values identified within three months of each 6-monthly 
evaluation period after ART initiation were included in the database.  All 
laboratory testing was performed by NHLS with ublic funds.  Within the 
NHLS lab, CD4 percentages are measured through the application of a dual-
platform, dual-color PanLeucogating CD45-assisted flow cytometry machine 
20.  Viral loads were initially performed using the NucliSens HIV-1 QT assay 
(bio-Merieux, Boxtel, the Netherlands), which yielded viral loads undetectable 
below 400 copies/ml.  Advances in sensitivity with the introduction of the 
NucliSens EasyQ HIV-q assay allowed more precise quantification of low-
level viremia, however all viral load values less than 400 copies/ml will be 
considered “suppressed”. 
Clinically significant virologic failure (VF) was defined as two sequential 
viral load values greater than 1,000 copies/ml.  Once patients with VF were 
identified, pediatric clinicians were asked to provide a clinical vignette 
describing adherence issues or the presumed underlying cause for failure.  
                                                













Maximal mortality was defined as documented deaths in addition to those lost 
to follow-up.  Survival analyses were calculated using the time to actual event 
or date of last evaluation. 
Research Ethics Committees at Stellenbosch University and the 
University of Cape Town provided approval of this project.  Additionally, 
permission to access patient health information was granted by the Deputy-
Director General of District Health Services and Programmes within the 




Data were compiled into Excel spreadsheets and uploaded to Stata 
Statistical Software version 10.0 (StataCorp. LP. College Station, TX, United 
States of America) for analysis.  Continuous variables were categorized by 
both ART initiation site (PHC vs. down-referred) and longevity within the PHC 
network (“baseline” vs. “longitudinal”) and explored for normalcy; all values 
were accordingly analyzed with non-parametric Wilcoxon sum rank test for 
sub-cohort comparisons.  Categorical frequencies were also stratified by ART 
initiation site and duration of care within the PHC network.  A two-sample test 
of proportion was utilized to detect differences between sub-group 
frequencies. 
Cox proportional hazards regression was performed to assess risk 
factors for maximal mortality (documented mortality and those lost to follow-
up); a model including the age at ART initiation and days on ART at 
censorship was statistically significant.  Kaplan-Meier survival analysis was 
performed to identify median time to VL suppression with stratification with 












logistic regression was performed to explore variables (including protease 
inhibitor-containing ART and TB co-infection) that may be related to the risk of 
developing VF 21.  Manual and automated model building were performed to 
create a best-fit model, which ultimately included ART initiation site and 
baseline viral load log.  Model diagnostics identified one patient that was both 
an outlier and influential point; the data for this patient was omitted from the 
model.  Although his exclusion did not alter the significance of variables 
included in the model, the child had clinical and laboratory characteristics 
consistent with long-term non-progression which was felt to be phenotypically 





A total of 848 patients were identified within the seven PHC ART clinics; 613 
met the inclusion criteria.  Two unique cohorts exist within the group of 
children cared for within the PHC network: those who initiated ART in one of 
the study clinics, and those who were down-referred from a higher level of 
care.   The majority of those ineligible for analysis were HIV infected patients 
who had not initiated ART before the end of our study period (see Figure 1).  
Baseline illness severity at the time of ART initiation, as measured by 
WHO clinical categorization, was significantly different between initiation sites; 
a larger proportion of severely ill children were started on ART at a higher 
level of care than a PHC clinic (p<0.001).  Additionally, those who were 
ultimately down-referred had significantly lower baseline CD4 percentages 
(p=0.016), higher viral loads (p<0.001), and greater likelihood of TB co-













Figure 1:  Study cohort profile 
 
ART initiation in 
PHC (n=343) 
 Down-referred on 
ART (n=270) 
  
Ineligible PHC patients (n=235) 
  
 
   153 (65%) = HIV infected, not on ART 
68 (29%) = dates of care in PHC not 
eligible by inclusion criteria 
7 (3%) = significant missing data 
5 (2%) = PHC not medical home 
2 (1%) = HIV exposed, uninfected 
PHC ART cohort (n=613)  
     
Baseline data 
(n=182) 

















Number of Children 613 343 270  
Gender 46% male 48% male 44% male 0.359           
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0.194          
0.419 
Baseline Viral Load 
Median (IQR)  
 
Baseline Viral Load log 
Median (IQR)  
270000 
(49182 - 1000000) 
 
5.4 
(4.69 – 6) 
230000 
(32000 - 830000) 
 
5.4 
(4.4 – 6) 
326969 
(87841 – 1554457) 
 
5.5 





TB at ART initiation 20.5% 16.9% 25.3% 0.013           
 
Similar trends in increased clinical severity (p<0.001) and higher 











for longitudinal analysis.  Due to the intensification of ART roll-out activities in 
the later half of the study period, the baseline cohort has a larger proportion of 
PHC-initiated patients, while the longitudinal cohort is skewed towards those 
down-referred (p<0.001) (see Figure 2).   
Figure 2: ART initiation by year and site 
Initial combination ART regimens were comprised of either two 
nucleoside reverse transcriptase inhibitors (NRTI) and a protease inhibitor (PI) 
(54%), or two NRTI drugs and one non-nucleoside reverse transcriptase 
inhibitor (NNRTI) (46%).  Lamivudine and stavudine were the most common 
NRTI drugs included in 99.5% and 86.7% of regimens respectively.
Lopinavir/ritonavir was the preferred PI, and efavirenz was the primary 
NNRTI. Those who were down-referred for ongoing care were on ART for a 
median of 23.2 months (IQR 13.6-34 months) at the time of transfer. 
The majority of children started on ART at any location had laboratory 
evidence of advanced or severe immunosuppressionii.  Those without 
ii Please see Part D: Appendices; Supplementary Tables, Figures; Table 1 for age-











immunosuppression, however, were significantly more likely to have initiated 
ART outside of the PHC system (p=0.017).  Infants in particular were more 
likely to receive ART without immunosuppression when care was initiated at 
the tertiary or district hospital level (p=0.027). 
Virological Outcomes
The median duration of follow-up was 28 months (IQR 16.5 – 42.6) including 
over 6 years of available dataiii for some children and a total of 1206 observed 
child-years.  Sustained high levels of viral load suppression were achieved at 
each time point (Figure 3), with approximately than 80% of the cohort 
suppressed from the 12-month visit.  At the last viral load measurement 
during the study period, 85% of the longitudinal cohort was suppressed. 
Figure 3: Virological, Immunological Outcomes over 5 years of ART
Kaplan-Meier survival analysis reveals a statistically significant 
difference in median time to VL suppression by ART initiation site: ART naïve 
patients who initiated care in the PHC system had a median time to 
iii Please see Part D: Appendices; Supplementary Tables, Figures; Table 3 for full 











suppression of 29 weeks, while those down-referred required 44 weeks 
(p<0.0001) (Figure 4).  Stratification by sex, age, baseline WHO immune 
categorization, modified South African WHO clinical stage, and TB co-
infection were not found to influence time to VL suppression. 
Figure 4: Time to Viral Load Suppression by ART Initiation Site 
Sixty patients (13.9%) met our criteria for clinically significant virological 
failure, representing an incidence of 5.4 cases per 100 child-years. Multiple 
logistic regression modeling revealed that patients who initiate ART in the 
PHC system are 66% [95% CI = 31%, 84%] less likely than those down-
referred to develop VF.  Additionally, for every one log increase in baseline VL 
the odds of developing VF doubles [95% CI = 1.3, 3.2].  Age, history of TB 
disease, protease inhibitor-based ART regimen with TB treatment, and 
baseline immune category were not found to be predictive of VF within the 
model; baseline WHO clinical classification, however, was so significantly 














Over 80% of the longitudinal cohort maintained a CD4% above baseline at 
each sequential monitoring period; a peak prevalence of 96% was achieved at 
36 months of ART (Figure 3).  The average percentage improvement over 
baseline CD4% was a median of 8.7% (IQR 2.3-13.8) at 6 months to a mean 
of 17.4% (95% CI 15.5-19.2) at 36 months.  Additionally, the largest 
proportion of those with more than 10% improvement in CD4% above 
baseline was achieved at 36 months.  Although CD4% gains drop off after 
three years of therapy, lower age-related norms over time are more likely 
underlying this finding rather than poor response to therapy given ever-rising 
VL suppression rates. 
Thirteen cases, two percent of children (1 per 100 child-years), had 
evidence of immunologic failure (IF)iv after at least 24 weeks of adherent ART 
treatment. Delayed immune reconstitution occurred in five IF children (38.5%); 
in this subgroup CD4 counts were recovered in 80% by 12 months and all 
children by 18 months of ART.  An additional five cases (38.5%) experienced 
transient IF despite concurrent VL suppression.  Although IF resolved by the 
subsequent interval evaluation, it should be noted that forty percent were 
undergoing concurrent TB treatment. It is therefore possible that intercurrent 
illnesses, TB or otherwise, may contribute to IF.  The remaining three children 
with IF (23%) had persistent failure despite ongoing VL suppression.  One 
persistent IF case experienced immune reconstitution after changing the 
protease inhibitor in her ART regimen from ritonavir to lopinavir/ritonavir. 
 
                                                
iv Please see Part D: Appendices; Supplementary Tables, Figures; Table 2 for age-














Documented mortality among the PHC cohort was 2.2% with a maximal 
mortality estimate (documented deaths and those lost to follow-up) of 6.2%. 
The relative risk of maximal mortality was found to decrease by 14.4% for 
every 3 months on ART, and by 15% for every 6 month increase in age at 
ART initiation.  A skewed temporal distribution of documented deaths was 
noted with near-equal numbers experiencing early (<3months on ART) and 
late (7-30 months on ART) mortality.  Similarly, a disproportionate number of 
children were lost to follow-up (LTFU) in the PHC-initiated group (p=0.028) 
concerning for undocumented early death after starting ART (Figure 5).  Long-
term maximal mortality rates (>6 months of care in a PHC clinic) did not differ 
by ART initiation site (p=0.091).  
 
Figure 5: Mortality and LTFU after ART initiation 
 
 
Due to left censoring of early deaths among the down-referred cohort, 












Early deaths occurred in either infants under 6 months of age, or young 
children (11-15 months old) with severe immunological suppression (CD4% 3-
8.2%).  Over half of the early mortality group (57%) died within the first 9 days 
of ART treatment.  Nearly half of those with early mortality were receiving dual 
therapy for HIV and TB disease (43%); TB treatment was started from 1 week 
to 3 months before ART initiation.  
 
Outcomes Among Children Down-referred from Tertiary Hospitals 
After a median of 2 years (IQR 13.6 – 34 months) on ART, 153 patients were 
down-referred from a tertiary facility to a PHC clinic. Approximately 80% had a 
suppressed VL at the time of down-referral, and 96% of these patients 
remained suppressed at the last measured study evaluation.  Of the 26 
patients transferred with sub-therapeutic response to ART, 77% achieved 
virologic suppression after 6 months of support and treatment within the PHC 
system.  Three quarters of the newly suppressed individuals met the criteria 
for VF at the time of transfer, yet only one third of these children required 
medication change to second line therapy to achieve successful suppression.  
Of the remaining 6 patients (23%) with ongoing VF, two were changed to 3TC 
mono-therapy; one was started on second line therapy immediately prior to 
the end of the study period whereby response to the intervention cannot be 
assessed; two made a lateral transfer to the adult ART roster within the same 
clinic; and only one patient required back-transfer to a tertiary care center.  
One down-referred child died within three months of transfer from a tertiary 
















Cohort characteristics reveal ART initiation site strongly correlates with 
WHO clinical severity, findings consistent with appropriate acuity triage within 
the public health services pyramid modelv.  Annually increasing absolute 
numbers of ART initiates, particularly less severely ill children within the PHC 
network, suggests successful ART roll-out strategies for pediatric patients in 
the Cape Town region 22.  Children receiving ongoing treatment within the 
PHC network demonstrated sustained indices of effective HIV management 
(high VL suppression rates, rapid immune reconstitution, low mortality rates) 
that are comparable, if not better, than those previously published studies of 
similar cohorts 15, 23-26. 
Despite overall low mortality, clear high-risk characteristics among 
children with documented death were identified: those in the first three months 
of ART treatment, infants less than 6 months or children under 15 months of 
age with severe immunological suppression at ART initiation, and those 
undergoing dual treatment for HIV and TB disease.  Similar trends in mortality 
have been noted in numerous studies 16, 25, 27, 28, providing further evidence of 
a focused time period among high-risk patients that may be ideal for a 
targeted intervention.  Intensified surveillance of this population would ideally 
result in expedited referral to higher levels of care and decreased mortality, 
however research at the health system level would be required to validate this 
theory. 
Although infants and young children are at higher risk for early mortality 
after ART initiation, evidence indicates that intervention before 12 weeks of 
                                                
v Please see Part D: Appendices; Supplementary Tables, Figures; Figure 1 for an 











age reduces this risk by 76% 29.  As a marker of early adoption of research-
based practice by physicians based in tertiary facilities (TBH was a CHER trial 
site), disproportionate amounts of non-immunosuppressed infants were found 
to be initiating ART at higher levels of care.  Although data to support 
asymptomatic infant ART initiation was first presented in mid-2007 at the 
International AIDS Conference on HIV Pathogenesis, Treatment and 
Prevention, recommendations were more widely disseminated through journal 
and WHO publications near the end of the study period in 2008 29, 30.  There is 
evidence of early adoption of infant ART roll-out in tertiary facilities, however 
the temporal nature of this study with respect to rapidly changing practice 
guidelines does not allow for true compliance evaluation. 
Data from the PHC network is unique in that it arises from the first 
exclusively pediatric cohort with down-referral longitudinal data.  Near perfect 
rates of sustained viral load suppression after tertiary-to-PHC down-referral is 
demonstrated among stable patients.  Optimistic outcomes among 
predominantly adult down-referred patients are congruent with our findings, 
however these studies likely suffer from selection bias (those offered down-
referral were pre-selected for success) 18, 19.  Unlike these studies, one out of 
every 5 down-referred child had an unsuppressed VL at the time of transfer.  
Among the unsuppressed, many had VF with clinicians noting adherence 
issues in most.  Although down-referred children had more cumulative ART 
exposure with associated risk for resistance development, a high proportion 
achieved viral suppression after transfer into the PHC network without ART 
regimen change.  Successful suppression on first line therapy for those 












decreased barriers to care within communities-based clinics.  PHC physicians 
demonstrated expertise in effectively managing those requiring second line 
therapy with rare referral back to tertiary care centers and low documented 
mortality rates.  Substantial improvement in VL suppression rates among this 
sub-group was observed whether a focus on adherence or a change to 
second-line therapy was prescribed, thereby validating the efficacy of this 
model of care for all-comers. 
Although results support favorable outcome measures, inherent 
characteristics of the study design may limit generalizability of findings to a 
larger health system.  Initial patient identification from PHC rosters resulted in 
a cohort generally comprised of a stable down-referred population, and less 
severely ill children started on ART in the outpatient PHC setting.  Children 
who suffer early mortality or are lost to follow-up prior to PHC down-referral 
are inherently unaccounted for in this analysis.  Low mortality rates in this 
cohort may significantly underestimate those noted at a health system level 
due to sampling bias.   
While many decentralization schemes aim to not only transfer care to 
community-based centers but to also task-shift care to non-physician staff, 
children in the PHC cohort received ongoing care by highly skilled physicians 
who specialize in pediatric HIV management.  Weekly roundtable case review 
meetings between PHC clinicians, TBH IDC pediatric infectious disease 
specialists, and a social worker ensured that complex cases were routinely 
discussed.  The majority of those down-referred from tertiary care sites in this 
cohort initiated ART at TBH and these children are therefore well known to the 












While direct physician care of HIV management, weekly review of cases with 
subspecialists, and continuity of care for many down-referred patients may 
yield optimal medical outcomes, this approach is time and resource intensive.  
Prospective research on a health system level must be pursued to explore if 
favorable outcomes can be maintained as sustainable task-shifting to a non-




Although the majority of children were severely ill at ART initiation, increasing 
proportions of less acutely unwell children are initiating ART annually.  One of 
main anticipated demographic shifts among pediatric cohorts is the 
widespread provision of ART to asymptomatic infants; rapid adoption of this 
WHO recommendation has been observed at the tertiary care level in Cape 
Town. 
 While awaiting uniform adoption of early ART initiation for infants, our 
data suggests intensified surveillance of children under 15 months of age for 
the first three months of ART may improve mortality statistics.  Reproducibly 
well-defined patient characteristics restricted to a discrete high-risk period 
yield a clear target for programmatic intervention.  
Long term ART management within PHC clinics by pediatric clinicians 
yields successful outcomes.  Down-referral of tertiary center-enrolled patients 
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Data Collection Tool 
 
Study Number  
Patient’s Initials  
Date of Birth // (dd/mm/yyyy) 
Clinic register number  
Clinic folder number  
Data Capturer’s Initials  
 
Demographics & Past Medical History: 
Date of first PHC ART clinic attendance date // (dd/mm/yyyy) 
Clinic Site: _____________________________ 
Referral clinic/hospital: _____________________________ 
Sex  (m/f)  
Date of ART initiation // (dd/mm/yyyy) 
ART regimen: 3TC  d4T  Kal  EFV  ABC  AZT  DdI  Rtv  
Baseline CD4   absolute 
Baseline CD4  . % 
Baseline VL   
Baseline viral log . 
Baseline WHO Stage  
6 months on ART 
Date of visit // (dd/mm/yyyy) 
ART regimen: 3TC  d4T  Kal  EFV  ABC  AZT  DdI  Rtv 
Date of regimen change // (dd/mm/yyyy) 
Reason for regimen change: policy change   toxicity   failure   TB tx  
other  
TB co-infection at this visit Yes  No  Unknown  
CD4   absolute 
CD4  . % 
VL   
viral log . 
WHO Stage  
 
12 months on ART 
Date of visit // (dd/mm/yyyy) 
ART regimen: 3TC  d4T  Kal  EFV  ABC  AZT  DdI  Rtv 
Date of regimen change // (dd/mm/yyyy) 
Reason for regimen change: policy change   toxicity   failure   TB tx  
other  
TB co-infection at this visit Yes  No  Unknown  
CD4   absolute 
CD4  . % 
VL   
viral log . 
WHO Stage  










Date of visit // (dd/mm/yyyy) 
ART regimen: 3TC  d4T  Kal  EFV  ABC  AZT  DdI  Rtv 
Date of regimen change // (dd/mm/yyyy) 
Reason for regimen change: policy change   toxicity   failure   TB tx  
other  
TB co-infection at this visit Yes  No  Unknown  
CD4   absolute 
CD4  . % 
VL   
viral log . 
WHO Stage  
 
24 months on ART 
Date of visit // (dd/mm/yyyy) 
ART regimen: 3TC  d4T  Kal  EFV  ABC  AZT  DdI  Rtv 
Date of regimen change // (dd/mm/yyyy) 
Reason for regimen change: policy change   toxicity   failure   TB tx  
other  
TB co-infection at this visit Yes  No  Unknown  
CD4   absolute 
CD4  . % 
VL   
viral log . 
WHO Stage  
 
30 months on ART 
Date of visit // (dd/mm/yyyy) 
ART regimen: 3TC  d4T  Kal  EFV  ABC  AZT  DdI  Rtv 
Date of regimen change // (dd/mm/yyyy) 
Reason for regimen change: policy change   toxicity   failure   TB tx  
other  
TB co-infection at this visit Yes  No  Unknown  
CD4   absolute 
CD4  . % 
VL   
viral log . 
WHO Stage  
 
36 months on ART 
Date of visit // (dd/mm/yyyy) 
ART regimen: 3TC  d4T  Kal  EFV  ABC  AZT  DdI  Rtv 
Date of regimen change // (dd/mm/yyyy) 
Reason for regimen change: policy change   toxicity   failure   TB tx  
other  
TB co-infection at this visit Yes  No  Unknown  
CD4   absolute 
CD4  . % 










viral log . 
WHO Stage  
 
42 months on ART 
Date of visit // (dd/mm/yyyy) 
ART regimen: 3TC  d4T  Kal  EFV  ABC  AZT  DdI  Rtv 
Date of regimen change // (dd/mm/yyyy) 
Reason for regimen change: policy change   toxicity   failure   TB tx  
other  
TB co-infection at this visit Yes  No  Unknown  
CD4   absolute 
CD4  . % 
VL   
viral log . 
WHO Stage  
 
48 months on ART 
Date of visit // (dd/mm/yyyy) 
ART regimen: 3TC  d4T  Kal  EFV  ABC  AZT  DdI  Rtv 
Date of regimen change // (dd/mm/yyyy) 
Reason for regimen change: policy change   toxicity   failure   TB tx  
other  
TB co-infection at this visit Yes  No  Unknown  
CD4   absolute 
CD4  . % 
VL   
viral log . 
WHO Stage  
 
54 months on ART 
Date of visit // (dd/mm/yyyy) 
ART regimen: 3TC  d4T  Kal  EFV  ABC  AZT  DdI  Rtv 
Date of regimen change // (dd/mm/yyyy) 
Reason for regimen change: policy change   toxicity   failure   TB tx  
other  
TB co-infection at this visit Yes  No  Unknown  
CD4   absolute 
CD4  . % 
VL   
viral log . 













Final Datapoint = Date of outcome // (dd/mm/yyyy) 
    Died  lost to follow-up  transferred out   end of study period (Jan 09) 
 
If alive and still at HIV clinic at final datapoint: 
  
 full virological suppression (VL=LDL) 
 incomplete virological suppression (VL < 1000 but > 400 [50] copies/ml) 
 virological failure (VL > 1000 c/ml) 
 
Number of episodes TB treatment:   
 
1. // to // 
2. // to // 













Comprehensive Literature Review Methods 
(Output as Performed on 7/12/11) 
Topic   PubMed Search Terms  Results 
(search#) 
Limits  Humans, Clinical Trial, Meta-analysis, Randomized 
Clinical Trial, Review, All Infant: birth-23 months, All 









“HIV Infections”[MeSH] OR “HIV”[MeSH] OR hiv [tw] OR
hiv-1*[tw] OR hiv-2*[tw] OR hiv1[tw] OR hiv2[tw] OR hiv
infect*[tw] OR human immunodeficiency virus[tw] OR
human immunedeficiency virus[tw] OR human immuno-
deficiency virus[tw] OR human immune-deficiency
virus[tw] OR ((human immun*) AND (deficiency
virus[tw])) OR acquired immunodeficiency syndrome[tw]
OR acquired immunedeficiency syndrome[tw] OR
acquired immuno-deficiency syndrome[tw] OR acquired
immune-deficiency syndrome[tw] OR ((acquired immun*)










Antiretroviral Therapy, Highly Active[MeSH] OR Anti-
Retroviral Agents[MeSH] OR Antiviral
Agents[MeSH:NoExp] OR ((anti) AND (hiv[tw])) OR
antiretroviral*[tw] OR ((anti) AND (retroviral*[tw])) OR
HAART[tw] OR ((anti) AND (acquired
immunodeficiency[tw])) OR ( (anti) AND (acquired
immunedeficiency[tw])) OR ((anti) AND (acquired
immunodeficiency[tw])) OR ( (anti) AND (acquired




Outcomes   viral load OR viral suppression OR virological
suppression OR response OR immunologic* OR
immune suppression OR immunosuppression OR
survival OR death OR mortality OR CD4
75,258 
#3 
Setting  Developing country OR resource-limited OR community 
OR community-based OR primary care OR primary 







Combine  #1 AND #2 AND #3 1,563 
#6 













Combine  #1 AND #2 AND #3 AND #5 275 
#8 




Excluded themes: HIV-negative patients, studies of adult 
patients only, studies in HIV-infected patients whose 
primary outcomes are not VL/CD4/survival outcome 
related (lipodystrophy, metabolic changes, wt change, 
growth, neurologic/cognitive outcomes, etc), HIV-
infected children’s outcomes before starting ART, 
PMTCT outcomes, cost-effectiveness studies, 
adherence studies, resistance studies, opinion pieces 
without novel data, outcomes for novel meds not 
available on SA formulary, HepC co-infection, HepB co-
infection, vaccine trials, Phase 1 Safety/PK studies, 
vaginal microbicides, studies of novel ART drugs for 
salvage therapy, outcomes after switch to 2nd line 
therapy after poor viral suppression, outcomes <6mo 
after ARTi, therapeutic drug level monitoring studies, 





Additional literature was acquired from mentors, 
identified as appropriate resources within the references 











Supplementary Tables, Figures 
Figure 1:  The Health Services Pyramid model demonstrates the theoretical 
proportion of hierarchical healthcare provision levels (ascension correlates 
with further specialization of health care providers and available services).  
Ideally primary and secondary prevention interventions result in smaller 
numbers of the population requiring access to higher-levels of more sub-
specialized care {{140 Gold 1994; 141 Turnock 2009;}}.  Within a context of 
pediatric ART management, population-based public health services refers to 
PMTCT and ABC campaign efforts; primary health care is the strata where 
our PHC network is located, and were we hope the majority of ART is 
eventually managed; the secondary health care level refers to district level 
hospitals where access to pediatric clinicians can likely be expected; and the 
tertiary health care summit references the three academic hospitals with 












Table 1:   
WHO Immunological categories by CD4% and absolute CD4 count for 
pediatric HIV infection 




Age >13 mo 
(1) 
>5 yrs (2) 
No sig immunosuppression (1) >35% >25% >500 cells/ul 
Mild immunosuppression (2) 25-34% 20-24% 350-499 cells/ul 
Advanced immunosuppression (3) 20-24% 15-19% 200-349 cells/ul 
Severe immunosuppression (4) <20% <15% <200 cells/ul 
 
Table 2:   
WHO Immunological failure is recognized as developing or returning to the 
following thresholds after at least 24 weeks on ART, in a treatment-adherent 
child: 
≥2 years to <5 years of age CD4 count of <200cells/mm3 or %CD4 < 10 
≥5 years of age CD4 count of <100 cells/mm3 
 
Table 3:   
Full longitudinal outcome data (n=431).  NB: Not all individuals will have both 
CD4 and VL values available at each lab evaluation period (i.e. “n” is different 




























6 months 327 76.76% 300 82.33% 41% 7 14.89 
12 months 317 80.44% 289 88.58% 58.13% 7 5.92 
18 months 232 78.45% 204 88.73% 60.78% 2 3.36 
24 months 212 80.19% 163 94.48% 72.39% 2 4.81 
30 months 162 83.95% 125 94.4% 72.8% 2 4.43 
36 months 137 89.05% 100 96% 80% 1 3.88 










48 months 68 85.29% 41 92.68% 73.17% 2 6.25 
54 months 39 92.31% 21 85.71% 57.14% 1 5.88 
60 months 22 95.45% 10 80% 50% 1 0 
66 months 10 90% 4 100% 100% --- 0 
72 months 6 50% 0 --- --- --- 0 
78 months 1 100% 0 --- --- --- 0 
Last 
capture 
 84.69%      
*VL (n) = “n” obs available at each time point; VL Suppression defined as 
≤400copies/ml; CD4% (n) = “n” obs available at each time point; CD4% Imp >10% = 
Percentage of follow-up CD4% levels that have risen more than 10% over 
baseline; %CD4%>BL = Percentage of follow-up CD4% levels that have maintained 
a value greater than baseline; WHO immunological failure is defined i  Table 2 – 
these values do not include elimination of those non-adherent (i.e. with concurrent 
elevated VL); TB refers to the proportion of patients with concurrent TB tx at the time 
of f/u evaluation (according to TB Rx start and either documented or presumed – 
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UNIVERSITI OF C'>"PE TO\>:;'N 
13 March 2009 
REC REF: 120/2009 
Dr MM Morsheimer 
Public Health & Family Medicine 
Dear Dr Morsheimer 
Heahh Scienoes Faculty 
Reseuch Ethics Committee 
Room ES2-24 Groote Schuur Hospital Old Main Building 
Observatory 7925 
Telephone [021] 406 6338 • Facsimile [021] 406 6411 
e-mail: Iamees.emjedi@uct.ac.za . 
PROJECT TI'ILE: SURVIVAL, VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES OF HIV-
INFECTED CHILDREN ACCESSING ART AT SOUTH AFRICAN PRIMARY HEALTH CARE 
CUNICS 
Thank you for submitting yoUl study to the Research Ethics Committee for review. 
It is a pleasure to infonn you that the Ethics Committee has formally approved the above-mentioned study 
Approval is granted for one year till the 20th March 2010. 
Approval is granted for a waiver of informed consent as participants' privacy and confidentiaIity will he 
protected and it would not be practical to obtain such consent. 
Approval was gnnted using ~n expedited review according to Category Number 5 of the OHRP Guidance. 
Please send us an annual progress report if your research continues beyond the approval period. Alternatively, 
please send us a brief summary of your findings so that we can close the research file. 
Please note that the ongoing ethical conduct of the study remains the responsibility of the principal 
inves rigator. 












PRO~BL~ tp CHAIRPERSON. HSF HUMAN ETIlleS 
Federal Wide Assurance Number. F\'!I:'A()()()01637. 
I rlStttutional Review Board (IRE) number: IRBOOO01938 
'Ibis serves to confirm that the University of Cape Town Research Ethics Committee complies to the Ethics 
S tandatds for Clinical Research with a new drug in patients, based on the Medical Research Council (MRC-
Sil.), Food and Drug Administration (FDA-USA), International Convention on Hamlonisation Good Clinical 
Practice (lCH GCp) and Declaration of Helsinki gcidelines. 
The Research Ethics Committee granting this approval is in compliance with the ICH Harmonise<! Tripartite 
Guidelines EO: Note for Guidance on Good Clinical Pnctice (CPMP/ICH/135/95) and FDA Code Federal 










UNIVERSITY OF CAPE TOWN 
FACULTY OF HEALTH SCIENCES 
Human Research Ethics Committee 
Annual Progress Report . 
Date 2 August 2010 
HREC REF Number 120/2009 
Protocol number (if Survival, virological and immunological outcomes of HIV-infected 
applicable) & Protocol children accessing ART at South African primary health care clinics 
title 
Principal Investigator Dr. Megan Morsheimer 
Department I Office 
Internal Mail Address 
megan.morsheimer@gmail.com 
List of documentation 
Annual Progress Report - Expedited review kindly requested 
HREC office use only (FWAoooo1637; IRBOO()019311) 
' . - .. c'.. ""'".,. '. ",." .,'_ '. ,, >-, ",_ '.... ., ,-' '-,- '.,'. d: ' ...... , .' . • _, 
O("Approved This serves asnotificatioh ofaruluaFapproval,ilicldding alidocumEmtatiofl described 
\ above.,' , . . 
o Not approved See,attached comments.' 




", .' . 
; 











UNIVERSity Of CAPt TOWN 
,. • II ". 'I' ••••• ,. •• FACUL TV OF HEALTH SCIENCES 
Human Research Ethics Committee 
Annual Progress Report 
Date 27 July 2011 
HREC REF Number 120/2009 
Protocol number (if Survival, virological and inununological outcomes of HIV -infected children 
applicable) & Protocol accessing ART at South African primary health care clinics 
title 
Principal Investigator Megan Morsheimer MD 
Department I Office Faculty of Health Sciences, School of Public Health 
Internal Mail Address 
.M.egan.lllQf~eimer@gllli!il.cmll.; morsheimerm@pds.ucsf.edu 
List of documentation 
Annual Progress Report - Expedited review kindly requested 
• .5 
HREC office use only (FWA00001637; IRBOOOO1938) 
o Approved V This serves as notification of an nual approval, including all documentation described 
above. 
o Not approved See attached comments. 
Type of review o Expedited l,.../ 0 Full committee 
Expiry date IS A u. (;r L\ ST 2 .. 012.. 
Signature 
~ffAt Mi~ 
Date 5& .f( Chairperson of the HREC 
v 1 










 24 March 2009  
 Dr MM Morsheimer 
 Department of Paediatrics 
 Stellenbosch University 
 Tygerberg 
 7505 
 Dear Dr Morsheimer 
 "Survival,virological and immunological outcomes of HIV-infected children accessing ART at South African primary  
 health care clinics." 
 ETHICS REFERENCE NO: N09/03/082 
 RE : PROVISIONAL APPROVAL 
 It is my pleasure to inform you that the abovementioned project has been provisionally approved on 
 21 March 2009 for a period of one year from this date.  You may start with the project, but this approval will however be  
 submitted at the next meeting of the Committee for Human Research for ratification, after which we will contact you  
 again. 
  
 Notwithstanding this approval, the Committee can request that work on this project be halted temporarily in anticipation of 
  more information that they might deem necessary to make their final decision. 
  
 Please quote the abovementioned project number in all future correspondence. 
  
 Please note that a progress report (obtainable on the website of our Division) should be submitted to the Committee  
 before the year has expired.  The Committee will then consider the continuation of the project for a further year (if  
 necessary). Annually a number of projects may be selected randomly and subjected to an external audit. 
  
 Please note that in line with the recent changes to research ethics guidelines, including the Declaration of Helsinki, the  
 CHR requires that all researchers specifically  request and motivate for a “waiver of informed consent” for retrospective  
 clinical audits. 
  
 Federal Wide Assurance Number: 00001372 











 The Committee for Human Research complies with the SA National Health Act No.61 2003 as it pertains to health  
 research and the United States Code of Federal Regulations Title 45 Part 46. This committee abides by the ethical norms 
  and principles for research, established by the Declaration of Helsinki, the South African Medical Research Council  
 Guidelines as well as the Guidelines for Ethical Research: Principles Structures and Processes 2004 (Department of  
26 March 2009 08:01 Page 1 of 2 
 Fakulteit Gesondheidswetenskappe ! Faculty of Health Sciences 
 Verbind tot Optimale Gesondheid · Committed to Optimal Health 
 Afdeling Navorsingsontwikkeling en -steun ! Division of Research Development and Support 
 Posbus/PO Box 19063 · Tygerberg 7505 · Suid-Afrika/South Africa 
 Tel.:  +27 21 938 9075 · Faks/Fax: +27 21 931 3352 
Yours faithfully 
 MRS MERTRUDE DAVIDS 
 RESEARCH DEVELOPMENT AND SUPPORT 
 Tel: 021 938 9207  /  E-mail: mertrude@sun.ac.za 
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 Verbind tot Optimale Gesondheid · Committed to Optimal Health 
 Afdeling Navorsingsontwikkeling en -steun ! Division of Research Development and Support 
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15 March 2012 
Dr A Dramowski 
Academic Unit: Infection Prevention & Control 
Div Community Health 
Stellenbosch University 
T ygerberg campus 
7505 
Dear Dr Dramowski 
MAILED 
"Survival, virological and immunological outcomes of HJV~infected children accessing ART at South African primary 
health care clinics." 
ETHICS REFERENCE NO: N09/03/0S2 
RE : PROGRESS REPORT 
At a meeting of the Health Research Ethics Committee that was held on 14 March 2012, the progress report for the 
abovementioned project has been approved and the study has been granted an extension for a period of one year from this 
date. 
Please remember to submit progress reports in good time for annual renewal in the standard HREC format. 
Approval Date: 14 March 2012 
Yours faithf y 
DEVELOPMENT AND SUPPORT 
Tel: 021 9389207 / E-mail: mertrude@sun.ac.za 
Fax: 021 931 3352 
30 May 2012 09:53 
Expiry Date: 14 March 2013 
Verbind tot Optimale Gesondheid . Committed to Optimal Health 
Afdeling Navorsingsontwikkeling en -steun . Division of Research Development and Support 
Posbus/PO Box 19063 . Tygerberg 7505 . Suid-Afrika/South Africa 
Tel.: +27 21 9389075 . Faks/Fax: +27 21 931 3352 
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